HIGHLIGHTS
- who: Tetsunori Sakamoto from the Department of Anatomy and Developmental Biology, Kyoto University Sakyou2011Ku, Kyoto, u20118501, Japan have published the Article: Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy, in the Journal: (JOURNAL)
- what: The authors report that the BCBL-1 u00adKSHV+ PEL cell line does not harbor oncogenic mutations responsible for its aggressive malignancy. The authors demonstrated that the CDK9 inhibitor FIT-039 suppressed the transcription of these KSHV viral genes, and administration of FIT-039 to the u00adKSHV+ PEL xenograft model of BCBL-1 cells led to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.